Core Insights - Assertio Holdings, Inc. reported financial results for Q4 and full year 2025, with net product sales and adjusted EBITDA exceeding guidance [1][5] - The company expects net product sales between $110 million and $125 million and adjusted EBITDA between $28 million and $40 million for FY2026 [1][5] Financial Highlights for Q4 2025 - Cash, cash equivalents, and short-term investments totaled $63.4 million as of December 31, 2025, down from $93.4 million as of September 30, 2025, primarily due to impacts from Rolvedon sell-in [4] - Adjusted EBITDA for Q4 2025 was a loss of $4.1 million, compared to earnings of $3.4 million in the prior-year quarter, mainly due to lower Rolvedon net product sales [4] - SG&A expenses decreased to $13.1 million from $21.4 million in the prior-year quarter, reflecting lower legal and personnel expenses [4] - Gross margin improved to 75% from 61% in the prior-year quarter, driven by sales product mix and prior-year inventory write-downs [4] - Rolvedon net product sales were $0.4 million for Q4 2025, down from $15.4 million in the prior-year quarter, due to a sell-in executed in Q3 2025 [4][5] Financial Highlights for Full Year 2025 - Cash, cash equivalents, and short-term investments totaled $63.4 million as of December 31, 2025, compared to $100.1 million as of December 31, 2024 [6] - Adjusted EBITDA for full-year 2025 was $22.7 million, up from $18.3 million in the prior year, primarily due to lower SG&A expenses and favorable gross margin [6] - SG&A expenses for full-year 2025 were $69.0 million, down from $75.1 million in the prior year [6] - Gross margin for 2025 was 70%, up from 68% in the prior year, mainly due to a decrease in inventory write-downs [6] - Rolvedon net product sales increased to $68.2 million for full-year 2025 from $60.1 million in the prior year, driven by higher volume and a favorable adjustment to prior period returns reserve [6] 2026 Financial Guidance - Assertio announced its initial 2026 operating guidance, projecting net product sales between $110 million and $125 million and adjusted EBITDA between $28 million and $40 million [1][5]

Core Viewpoint - Rafael Holdings, Inc. reported its financial results for the second quarter of fiscal year 2026, highlighting ongoing clinical trials and financial performance, including increased net losses attributed to the consolidation of Cyclo Therapeutics' expenses following its acquisition. Financial Performance - As of January 31, 2026, the company had cash and cash equivalents of $37.8 million [4] - For the three months ended January 31, 2026, the net loss attributable to Rafael Holdings was $6.4 million, or $0.13 per share, compared to a net loss of $4.6 million, or $0.19 per share in the same period last year [5] - Research and development expenses for the same period were $4.5 million, up from $0.9 million year-over-year, primarily due to the inclusion of Cyclo's expenses [6] - General and administrative expenses were $2.3 million, a decrease from $2.6 million in the prior year, attributed to reduced payroll and professional fees [7] - For the six months ended January 31, 2026, the net loss was $16.2 million, or $0.32 per share, compared to a net loss of $13.6 million, or $0.57 per share in the previous year [8] Clinical Development - The company is progressing with its pivotal Phase 3 TransportNPC™ study evaluating Trappsol Cyclo™ for Niemann-Pick Disease Type C1, with the Data Monitoring Committee recommending continuation after reviewing safety and efficacy data at 48 weeks [2] - The Phase 3 clinical trial is the largest ever conducted for this indication, with preliminary top-line results expected in the third quarter of 2026 [3] Company Overview - Rafael Holdings, Inc. is a biotechnology company focused on developing pharmaceuticals and holding interests in clinical and early-stage companies [11] - The lead candidate, Trappsol Cyclo™, is under evaluation for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disorder [11]

Core Viewpoint - A class action lawsuit has been filed against Soleno Therapeutics, Inc. regarding alleged safety concerns related to its drug DCCR, marketed as VYKAT XR, which could impact the company's commercial viability and shareholder interests [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Soleno's Phase 3 clinical trial for DCCR downplayed significant safety concerns, including risks of fluid retention, diabetes, and pulmonary edema [2]. - The lead plaintiff deadline for the lawsuit is set for May 5, 2026 [2]. Group 2: Drug Profile and Financials - DCCR is the first FDA-approved treatment for hyperphagia in individuals with Prader-Willi syndrome, affecting an estimated 300,000 to 400,000 individuals globally [3]. - The drug is priced at approximately $500,000 per year per patient, generating $32.7 million in net revenue from sales during the quarter ended June 30, 2025 [3]. Group 3: Safety Allegations - The lawsuit alleges that the commercial viability of DCCR relied on the integrity of safety data, which was allegedly concealed, threatening patient adoption and prescriber willingness [4]. - Key safety allegations include: - Diazoxide's mechanism causing fluid retention, leading to potential pulmonary edema and heart failure [5]. - An alarming increase in prediabetes and diabetes within 13 weeks of starting DCCR, with a linear increase over three years [5]. - Reports of serious side effects, including hospitalizations and inability to walk due to fluid buildup [5]. - A steady increase of 16 pounds in fluid retention over three years, mischaracterized as an increase in lean body mass [5]. Group 4: Regulatory and Disclosure Issues - The case raises important questions about drug safety disclosure obligations in the rare disease pharmaceutical sector, emphasizing that shareholders should be informed of undisclosed safety risks [6]. - The lawsuit alleges that the known risks associated with diazoxide were not adequately disclosed to investors, and the clinical trials were structured to minimize the appearance of these risks [7].

Core Insights - Pfizer (PFE) and Bristol Myers (BMY) hold significant positions in the oncology market, which is expected to grow due to rising cancer patient numbers [2][3] - Both companies have strong fundamentals and growth drivers, making them attractive investment opportunities [3] Pfizer Overview - Pfizer's oncology portfolio includes various modalities such as small molecules and antibody-drug conjugates (ADCs), targeting multiple cancer types [4] - Key approved drugs include Ibrance, Xtandi, and Padcev, with Ibrance being a major revenue contributor [5] - The acquisition of Seagen in December 2023 enhanced Pfizer's oncology portfolio, adding four ADCs and expected to boost sales in 2025 [6] - Pfizer's oncology biosimilars generated $1.3 billion in sales in 2025, reflecting a 26% year-over-year increase [7] - The company anticipates having eight or more blockbuster oncology medicines by 2030 [8] Bristol Myers Overview - Bristol Myers focuses on immuno-oncology (IO) and has a strong portfolio with drugs like Opdivo and Yervoy [10] - The FDA approval of a new subcutaneous formulation of Opdivo is expected to enhance its market reach [11] - Recent acquisitions, including Mirati and RayzeBio, have expanded its oncology pipeline [12][14] - Krazati, a KRAS inhibitor, is approved for specific lung cancer treatments and is in further development [13] - The collaboration with BioNTech aims to develop bispecific antibodies for various solid tumors [16] Financial Estimates - For 2026, Pfizer's sales are estimated to decrease by 2.51%, while earnings per share (EPS) are expected to decline by 7.76% [17] - In contrast, Bristol Myers' sales are projected to decrease by 2.44%, but EPS is expected to increase by 1.79% [19] Price Performance and Valuation - Year-to-date, Pfizer's shares have increased by 2%, while Bristol Myers' shares have decreased by 1.5% [22] - In terms of valuation, Bristol Myers trades at a forward P/E ratio of 9.49, slightly higher than Pfizer's 9.04 [22] - Pfizer offers a higher dividend yield of 6.47% compared to Bristol Myers' 4.27% [23] Investment Consideration - Both companies are seen as safe investments in the pharma/biotech sector, but Pfizer is currently viewed as a better pick due to its attractive valuation and diversified portfolio [24][26]

Core Viewpoint - Amneal Pharmaceuticals, Inc. (AMRX) has shown positive stock performance since receiving a Buy rating a year ago, indicating a successful investment call [1]. Group 1: Company Overview - Amneal Pharmaceuticals, Inc. is highlighted as a stock that has performed well, with a significant increase in value since the last analysis [1]. Group 2: Analyst Background - The analysis is conducted by a biotech consultant with over 5 years of experience in the biotech, healthcare, and pharma sectors, having prepared detailed reports on more than 1,000 companies [1]. - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts, buy and sell ratings, product sales forecasts, and financial analyses [1].

Core Insights - GSK's RSV vaccine, Arexvy, received FDA approval for expanded use in adults aged 18 to 49 years at higher risk of lower respiratory tract disease (LRTD) [1][3] - Year-to-date, GSK's shares have increased by 8.8%, outperforming the industry growth of 2.7% [2] - The FDA's approval was based on late-stage study data showing Arexvy's immune response comparable to that of adults aged 60 and older, with a consistent safety profile [3] Regulatory Approvals - The European Commission approved Arexvy for all adults aged 18 years and older to prevent RSV-related LRTD, expanding from previous approvals for those aged 60 and older and high-risk individuals aged 50 to 59 years [4] - GSK's regulatory application for Arexvy in China for adults aged 60 years and above has been accepted, with a final decision expected in 2027 [5] Market Context - With the recent FDA approval, Arexvy becomes the third FDA-approved RSV vaccine for younger adults, alongside Pfizer's Abrysvo and Moderna's mResvia [6] - Pfizer's Abrysvo is also approved for pregnant individuals, making it unique in providing maternal immunization to protect infants against RSV [10] - Moderna's mResvia is approved for older adults aged 60 years and above and for high-risk adults aged 18 to 59 years [11] Sales Performance - Arexvy recorded global sales of £0.6 billion in 2025, reflecting a 2% increase at constant exchange rates, driven by growth in ex-U.S. markets despite declining sales in the U.S. due to slower uptake among the 60-plus population [12]

Core Insights - Johnson & Johnson (JNJ) reported positive results from an early-stage study of its investigational drug delivery system, Erda-iDRS, for treating intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) [1][3] Group 1: Study Results - The phase I study demonstrated that Erda-iDRS met its primary safety endpoint and showed encouraging clinical activity, with an 89% complete response (CR) rate in the intermediate-risk cohort and a median response duration of 18 months [6][7] - In the high-risk cohort, patients exhibited a median recurrence-free survival of 20 months, with an 83% recurrence-free survival rate at 12 months [8] - The treatment was well-tolerated, with no dose-limiting toxicities and most adverse events being mild to moderate [9] Group 2: Study Population and Design - The study included patients with recurrent intermediate-risk NMIBC and high-risk disease who had previously experienced Bacillus Calmette-Guérin (BCG) therapy, specifically targeting those with FGFR alterations [4][6] - A total of 62 patients in the intermediate-risk group and 26 in the high-risk group were treated as of November 3, 2025 [4] Group 3: Future Development - Positive findings from the early-stage study support ongoing phase II and III studies under J&J's MoonRISe program, which aims to evaluate Erda-iDRS across various NMIBC risk settings [10][12] - The program includes multiple studies, such as MoonRISe-1 for adjuvant treatment post-tumor resection and MoonRISe-3 for high-risk patients previously treated with BCG [12]

Group 1 - The article discusses Eledon Pharmaceuticals, Inc. (ELDN) and its role in the immunosuppressive drug space, particularly focusing on the drug Tegoprubart [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and provides in-depth analysis through the Biotech Analysis Central service, which includes a library of over 600 articles and a model portfolio [2] - The service offers a subscription model with a monthly fee of $49 and an annual plan at a discounted rate of $399, which represents a 33.50% discount [1] Group 2 - The article does not contain any disclosures regarding stock positions or plans to initiate positions in the companies mentioned, indicating an unbiased perspective [3] - Seeking Alpha emphasizes that past performance does not guarantee future results and that the views expressed may not reflect the overall opinions of the platform [4]

Core Points - ALK-Abelló A/S held its Annual General Meeting on March 16, 2026, where several key resolutions were passed [1] Group 1: Financial Performance - The annual report for 2025 was approved, and the Board of Directors and Board of Management were discharged [4] - An ordinary dividend of DKK 1.6 per share was declared, totaling DKK 355 million, with a remaining net profit of DKK 842 million carried forward [4] Group 2: Governance - The remuneration report for 2025 was adopted, along with the remuneration for the Board of Directors for the current year [4] - Anders Hedegaard was re-elected as Chair of the Board of Directors, and Lene Skole was re-elected as Vice Chair [4] - Other board members re-elected include Gitte Aabo, Lars Holmqvist, Jesper Høiland, Bertil Lindmark, and Alan Main [4] - PwC Statsautoriseret Revisionspartnerselskab was re-appointed as the company's auditor for statutory financial and sustainability reporting [4] - The updated remuneration policy proposed by the Board of Directors was approved [4] Group 3: Company Overview - ALK is a global specialty pharmaceutical company focused on allergy, covering the entire value chain from development to marketing of products for respiratory allergies and anaphylaxis [2]

Novartis AG is seeking to raise debt to help fund its $12 billion acquisition of Avidity Biosciences Inc, adding to a flurry of M&A financing deals. https://t.co/8keI0bVoly ...